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Lysophospholipids are lipid molecules that are receiving growing attention because, in addition to their
structural function in the cell membrane, they are now regarded as important regulators for diverse
biological functions through activation of specific receptors. These receptors have been characterized
during the last two decades as G protein-coupled receptors (GPCRs) and, among them, two families
stand out: lysophosphatidic acid (LPA1–6) and sphingosine 1-phoshate (S1P1–5) receptors. Despite their
interest, the high structural similarity between them has restrained the development of selective and high
affinity ligands and therefore the elucidation of the role of these receptors in the central nervous system
(CNS). This review provides an overview about the different LPA receptors with a special focus on the
LPA1 subtype from a medicinal chemistry perspective. It summarizes the most recent developments in
the search for selective and specific agonists and antagonists of the LPA1 receptor and highlights their
current status in the drug development pipeline.20
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The phospholipid superfamily has been traditionally linked to
structural roles, as key constituents of biological membranes.
Nevertheless, research from the last decades has associated
some phospholipids with diverse signalling functions, report-
ing their action as extracellular signals and, moreover,
their involvement in many physiological and pathological
processes.1,2
Phospholipids are usually divided into two broad families: (i)
glycerophospholipids,3 which are structurally based on the
glycerol scaffold (Fig. 1A) and (ii) sphingophospholipids, which
are derivatives of the amino alcohol sphingosine (Fig. 1B). They
present a polar head bearing a phosphate group (–OPO3Y
, Y¼H,
choline, ethanolamine, Fig. 1A and B) and two hydrophobic
chains (R, X, Fig. 1A and B). When one of the fatty acid chains is
missing (X ¼ H, Fig. 1A and B), the resulting derivatives are
denominated lysophospholipids. These molecules are quanti-
tatively minor lipid species compared to their parent
compounds, the phospholipids – which have a major presence
in cell membranes. Despite their low concentration, lysophos-
pholipids are important because of their ability to signal
through G protein-coupled receptors (GPCRs). Lysophosphati-
dic acid (LPA, 1-acyl-sn-glycero-3-phosphate, Fig. 1C) and
sphingosine 1-phosphate3 (S1P, Fig. 1D) are the two most
prominent molecules of this family, which are being extensivelyltad de Ciencias Qu´ımicas, Universidad
drid, Spain. E-mail: mluzlr@ucm.es;
hemistry 2014studied and their biological activities have been shown to be
extremely relevant.4
Although they belong to distinct signalling systems, simi-
larities between these two lipids extend to their tissue distri-
bution and concentration, homology and effector pathways of
their cognate receptors, and the broad range of their biological
roles. In contrast, the actions of other lysophospholipids have
not been elucidated to such a high degree and very little is
known about their endogenous receptors. However, recent in
vitro studies suggest that they can induce various and unique
cellular responses.5
Among the bioactive phospholipids, LPA stands out as a
molecule that elicits a plethora of biological effects, both in theFig. 1 General structure of common glycerophospholipids (A) and
sphingophospholipids (B). Structures of LPA (C) and S1P (D).
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20central nervous system (CNS) and in the periphery, by acting on
at least six different receptors. Nonetheless, its therapeutic
potential is still far from being established given the complexity
of the system and the lack of specic ligands, agonists and
antagonists, that enable the elucidation of the (patho)physio-
logical roles played by a particular LPA receptor subtype. This
review summarizes the most important aspects of the LPA
signaling system with a special focus on the LPA1 receptor, its
ligands and their potential for drug development. In the rst
part, we provide an overview of the different LPA receptors with
particular attention to the LPA1 subtype, its endogenous ligand
LPA, and the main (patho)physiological functions regulated by
the LPA1 receptor. Although more exhaustive reviews have been
published on the molecular, biochemical and pharmacological
aspects of the complex LPA system (see references), this intro-
duction will allow us to proceed to the second part of the review,
in which we address, from a medicinal chemistry perspective,
the most essential advances reported so far regarding the
development of selective and specic ligands of the LPA1
receptor. Finally, we will summarize the current status and the
clinical perspectives of the compounds that have progressed
most in the drug development pipeline.Fig. 2 Schematic representation of the signalling pathways activated
by the LPA1–6 receptors. The heterotrimeric G proteins are defined
here by their a subunits in orange (green and purple circles represent
the b and g subunits).
25
30
35
40
45
50
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LPA has a well-known structural function as a precursor and a
metabolite in the biosynthesis of membrane phospholipids.
However, it was not until the 1960s that several groups started
to report biological actions mediated by LPA, such as smooth
muscle contraction and platelet aggregation.6 Nevertheless, the
specic function of this intriguing molecule was still unknown.
During the mid-1980s, proliferative LPA-dependent effects in
broblasts were described. These responses were completely
inhibited with pertussis toxin pre-treatment, which specically
inactivates Gai/o-type G proteins.7 This was followed by the
description in the early 1990s of several morphological cell
changes attributed to LPA, such as cell growth, cell rounding/
neurite retraction8,9 and actin stress ber formation.10 At the
same time, S1P was reported to evoke cellular responses similar
to those induced by LPA, suggesting that they might even share
the same GPCRs.11
Growing evidence was making clear that LPA was acting
through a GPCR, as it was nally demonstrated by van Blit-
terswijk12 through photoaffinity labeling experiments, which
revealed [32P] LPA-binding membrane proteins of 38–40 kDa
present in various LPA-responsive cell types and in the brain.
This binding protein met all the pharmacological criteria for a
specic, high-affinity LPA receptor since its labeling was
competitively and specically inhibited by unlabeled LPA with
an IC50 as low as 10 nM. In addition to the LPA responses, LPA
binding was not detectable in LPA-unresponsive cells such as
human neutrophils, and was blocked by suramin, a known
inhibitor of LPA actions. Although similar evidences were
shown independently by Clark,13 the biophysical properties of
LPA or the possibility of second messenger activities were also
proposed as alternative mechanisms for LPA actions, and this2 | Med. Chem. Commun., 2014, xx, 1–11ambiguity persisted in the absence of molecularly identied
receptors.
Finally, in 1996, Chun and coworkers reported the discovery
of the rst lysophospholipid receptor gene, ventricular zone gene
1 (vzg-1),14 during their studies on mammalian neurogenesis.
Vzg-1 encoded a GPCR that had the properties of a high-affinity
LPA receptor. Identication of this gene as encoding an LPA
receptor was independently demonstrated by Goetzl15 and Kie-
fer.16 Denitive conrmation about the identity of this receptor
was achieved by heterologous expression in mammalian cells17
and genetic deletion of the receptor.18
Similar approaches allowed the identication of new recep-
tors, like the rst receptor for S1P, which was independently
reported by two groups in 1998.19,20 Since then, several members
of the orphan GPCR receptor family called “endothelial differ-
entiation genes” (Edg) were identied as GPCRs for both LPA
and S1P, including Edg4 (LPA2),21,22 Edg7 (LPA3),23 Edg5 (S1P2),
Edg3 (S1P3), Edg6 (S1P4)24 and Edg8 (S1P5).25 Regarding the LPA
receptors, another group of less similar GPCR genes have also
been identied, which are GPR23 (LPA4),26,27 GPR92 (LPA5),28,29
and P2Y5 (LPA6).30,31 This latter group is more closely related to
the family of P2Y purinergic receptor genes, indicating that LPA
receptors have evolved via two distinct lineages in the
rhodopsin GPCR family. To date, a total of eleven receptors have
been described, six for LPA (LPA1–6) and ve for S1P (S1P1–5).
The current nomenclature includes the cognate ligand and the
chronological order of identication. All LPA receptors are type
I, rhodopsin-like GPCRs that differ in their tissue distribution
and downstream signalling pathways32 (see Fig. 2 and Table 1
for a summary of some relevant features).LPA1 receptor
The mammalian LPAR1 gene encodes a 41 kDa protein of 364
amino acids with seven putative transmembrane domains.This journal is © The Royal Society of Chemistry 2014
Table 1 Summary of the most relevant features of LPA receptors
Namea
Gene symbol
(human)
Chromosomal location
(human)
Number of amino
acids (human)
Similarity to
LPA1 (%)
LPA1 LPAR1 9q31.3 364
LPA2 LPAR2 19p12 348 60
LPA3 LPAR3 1p22.3 p31.1 353 50
LPA4 LPAR4 Xq13–q21.1 370 10
LPA5 LPAR5 12p 13.31 372 12
LPA6 LPAR6 13q14 344 13
a Nomenclature of the International Union of Basic and Clinical Pharmacology (IUPHAR).
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55Human LPAR1 is widely expressed in the heart, brain,
placenta, skeletal muscle, kidney, pancreas, spleen, prostate,
testis, ovary, small intestine and colon.33 A similar distribution
is observed for the Lpar1 mouse gene, although it is more
spatially restricted during embryogenesis, where it is mainly
found in the ventricular zone (VZ), a major site for neuro-
progenitor cell proliferation during prenatal developmental
stages. VZ disappears prior to birth, reappearing during the
postnatal life within oligodendrocytes and Schwann cells that
may inuence myelination in the central and peripheral
nervous system, indicating roles for LPA signalling in cortical
development.34
Signalling through LPA1 receptor induces a range of cellular
responses: cell proliferation and survival, cell migration and
cytoskeletal changes. At the molecular level, LPA1 receptor acti-
vation can be transduced through three types of G proteins: Gai/o,
Gaq/11, and Ga12/13, that are responsible for Ca
2+ mobilization,
adenylyl cyclase inhibition and activation of phospholipase C, Akt,
Rho and mitogen-activated protein kinase pathways.
The targeted disruption of Lpar1 in mice revealed unantici-
pated in vivo functions of this receptor. Lpar1/ mice show
50% perinatal lethality and survivors have a reduced body size,
craniofacial dysmorphism, and increased apoptosis in sciatic
nerve Schwann cells.18
Other LPA receptors
Together with the LPA1 receptor, LPA2 and LPA3 have been the
most thoroughly studied ones. The expression pattern of the
LPA2 receptor is more spatiotemporally restricted compared to
the LPA1 receptor. Lpar2 is found in the embryonic brain, but its
expression strongly attenuates one week aer birth. In humans,
LPAR2 is found in the testis, leukocytes, prostate, spleen,
thymus and pancreas.32 LPA2 null mice35 were born normally
and showed no obvious behavioural, anatomical or histological
abnormalities, in contrast to LPA1 null mice.35 When LPA1/LPA2
double-null mice were generated, aggravation of the phenotypic
abnormalities was expected, as LPA2 is coexpressed with LPA1 in
several organs and cells and thus a major loss of LPA signalling
would be achieved. However, no qualitative differences in
phenotypes, compared to LPA1 null mice, were observed. Thus,
LPA1 and LPA2 receptors may have redundant functions in LPA
signalling.
LPAR3 encodes an 40 kDa GPCR broadly expressed in
humans. This receptor shows a strong preference forThis journal is © The Royal Society of Chemistry 2014unsaturated chains and has a relatively high affinity for 2-acyl-
LPA containing unsaturated fatty acids. Despite the fact that
LPA3 is expressed in the frontal cortex, hippocampus, and
amygdala, no phenotypes related to LPA3 loss in the nervous
system have been reported to date.32,43
The LPA4 receptor is structurally distinct from classical LPA1–3
and S1P receptors that share signicant homology, and is more
closely related to P2Y purinergic receptors. It does not, however,
respond to any nucleotide or nucleoside tested. LPA4 is ubiq-
uitously expressed in both humans and mice and it is speci-
cally abundant in the ovary. LPA5 (GPR92) was identied by two
independent groups in 2005 from the receptor gene data bank.
This receptor is structurally different to LPA1–3, but shares 35%
homology with LPA4. Lpar5 is relatively broadly expressed in
murine and human tissues.32,43
The orphan receptor P2Y5, closely related to the purinergic
family and sharing high homology with LPA4 receptor, has been
recently classied as the LPA6 receptor.31 This receptor has been
found to be essential for the maintenance of hair growth.36
Recently other receptors have been proposed. GPR87 and
P2Y10 are orphan GPCRs that have been described to be
responsive either to LPA or to both LPA and S1P, respectively.
They belong to the P2Y family and are similar to LPA4 and LPA5
receptors.37
Among all LPA actions, those elicited through LPA1–3
receptors have been the most studied to date, revealing crucial
roles in the nervous, vascular, immune and reproductive
systems. Focusing on the CNS, LPA1 is described as the receptor
with a major expression and, even though, the information is
very scarce, there is evidence enough to suggest that it can
contribute to the pathogenesis of several diseases and, accord-
ingly, could be endowed with therapeutic relevance for the
treatment of CNS disorders.
Lysophosphatidic acid receptor
structure
Currently, no crystal structures have been elucidated for any
native LPA receptor. The only phospholipid GPCR crystal
structure available is the structure of S1P1,38 which has provided
valuable information about the receptor–ligand interaction of
this type of receptor.39 This is especially useful for molecular
modelling of LPA receptors, because they share much higher
sequence homology with this receptor than with any of theMed. Chem. Commun., 2014, xx, 1–11 | 3
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25other currently available GPCR crystal structures, a fact that will
enable the construction of homology models of LPA1–3 receptors
using the structure of the S1P1 receptor as the template.40
Mutagenesis studies combined with computational analysis
identied several important residues in LPA1–3 receptors, most
of them located in transmembrane domains.41,42 In this regard,
Arg3.28 is important for efficacy and potency for all three
receptors, as it forms a salt bridge with the phosphate group
while Gln3.29 interacts with the hydroxy group of LPA. Thus,
this latter position is responsible for LPA/S1P selectivity, as S1P
receptors bear glutamic acid instead. These two residues are
conserved over the LPA1–3 receptors, together with Trp4.64,
which, in contrast, is only implicated in LPA3 activation. Other
amino acids important for ligand recognition and selectivity
among the LPA1–3 and S1P receptors are found in positions 5.38
(Asp in LPA1) and 7.36 (Lys in LPA1), though their function is
still not clear. LPA4 and LPA5 share less amino acid identity with
LPA1–3, and detailed models of their interaction with LPA are
not available. Most of the residues described above are not
present in LPA4 and LPA5, suggesting that these receptors have
different ligand binding characteristics. Further research is
needed to identify the critical residues for these receptors, and
this information will need to be re-evaluated once crystal
structure data become available.4330
35
40Biosynthesis and degradation of LPA
LPA is generally known as a mixture of various lysophospholi-
pids with both saturated (16 : 0, 18 : 0) and unsaturated (16 : 1,
18 : 1, 18 : 2, 20 : 4) fatty acid chains. It must be noted that in
the context of LPA as a signalling molecule, and thus
throughout this review, LPA refers to 1-oleoyl-sn-glycero-3-
phosphate. It is found in almost all eukaryotic tissues and
biological uids, including blood.32 Among them, serum is the
best characterized source of LPA, where it is bound to albumin
and other proteins, probably preventing the molecule from
rapid degradation.44
Autotaxin (ATX),45,46 a secreted glycoprotein with lysophos-
pholipase D activity, is the primary enzyme responsible for LPAFig. 3 Pathway for LPA production.
4 | Med. Chem. Commun., 2014, xx, 1–11production in blood. In fact, ATX heterozygote knockout mice
have a 50% reduction of circulating LPA compared to wild type
mice47 and negligible levels of LPA are detected aer treatment
with ATX inhibitors.48 Outside the cell, the enzyme ATX converts
lysophosphatidylcholine (LPC), produced from different
membrane phospholipids via phospholipase A2 (PLA2), into LPA
(Fig. 3).
Degradation of LPA can occur through two main routes. In
the rst one, LPA is irreversibly dephosphorylated to mon-
acylglycerol by lipid phosphate phosphohydrolases, presumably
LPP1. In the second route, LPA is reversibly esteried to phos-
phatidic acid (PA) by the enzyme LPA-acyltransferase (LPAAT).49Physiological roles of the LPA1 receptor
and therapeutic potential
LPA displays a wide range of cellular effects through its recep-
tors. Among the most important actions of LPA, those mediated
by the LPA1 receptor in the CNS stand out, a fact that immedi-
ately suggests a potential for the treatment of related diseases.45
50
55Nervous system
As highlighted before, the nervous system is one of the major
locations for LPA receptors,34 as they are expressed inmost of its
cell types under physiological and pathological conditions. In
addition, LPA can be found in the brain in high concentrations,
inuencing many developmental processes and neurological
disorders.
Among the different LPA receptors, the LPA1 subtype is the
most abundant one in the brain,32 where it plays a major role in
the development of the embryonic brain and thus in neuro-
genesis, due to its main expression in the VZ of the embryonic
brain. Neural progenitor cells (NPCs) – the differentiable cells
responsible for neurogenesis – express LPA1–3 receptors and are
found in this area, where they proliferate and sequentially
differentiate into various cell types, such as neurons, astrocytes
or oligodendrocytes.
Several in vitro and in vivo studies have demonstrated that LPA
controls proliferation and differentiation of NPCs via LPA1.
Furthermore, LPA1 null NPCs do not present the ability to achieve
LPA-dependent neurogenesis-related changes, conrming LPA1 as
a modulator of neurogenesis. In adult neurons, LPA is known to
inuence neuronal survival/death processes. Moreover, it has
been described that LPA1 is related to neuroprotection, as
apoptotic cell death is described in LPA1 null mouse brains.34
Neuropsychiatric disorders, like schizophrenia, anxiety,
memory impairment or Alzheimer's disease, have been recently
linked to LPA signalling. LPA1 null mutants share schizo-
phrenia-type defects, such as pre-pulse inhibition, serotonin
synthesis alteration or cranial dysmorphism. In addition, LPA
signalling through LPA1 in the hippocampus modulates neu-
rogenesis, which is related to learning and emotional behav-
iour; and memory impairments have been reported in LPA1
decient mice.34
Two important developmental disorders linked to the LPA1
receptor are: fetal hypoxia and fetal hydrocephalus. It wasThis journal is © The Royal Society of Chemistry 2014
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30shown that mouse brains exposed to LPA develop fetal hydro-
cephalus, and that treatment with an LPA1 antagonist blocked
this response, demonstrating the implication of the receptor.50
Regarding fetal hypoxia, it has been described that the absence
of the adequate supply of oxygen causes cortical disorganization
throughout NPCs via over-activation of the LPA1 receptor.51
Since both diseases are associated with later development of
CNS disorders, such as epilepsy, schizophrenia or autism, it is
clear that LPA1 signalling needs to be tightly regulated to ensure
unaltered brain functions.
LPA1 has also been associated with myelination because its
expression in oligodendrocytes (CNS myelinating cells) corre-
lates spatiotemporally with their maturation and myelination,
and it has been shown that LPA inuences several of its cellular
responses. Moreover, a recent study has shown that LPA, acting
through the LPA1 receptor, promotes Schwann cell migration,
which precedes myelination and remyelination in the periph-
eral nervous system.52
It has been suggested that LPA plays a key role in the initi-
ation of neuropathic pain, a form of chronic pain which
accounts for almost 20% of its diagnosed cases in the U.S.A.
Neuropathic pain is the result of a combination of multiple
factors, but a direct link with ber demyelination has been
reported.53 LPA produces nerve injury via LPA1-mediated
demyelination with subsequent loss of the structural and
functional integrity of neurons. In further support of this, LPA1
decient mice do not show neuropathic pain behaviour or
demyelination in response to intrathecal LPA injection or nerve
injury. LPA5 null mice are also protected from developing neu-
rophatic pain, although the mechanisms involved are different
from those mediated by LPA1.543
35
40
45
50
55Peripheral roles of the LPA1 receptor
Themain peripheral roles of LPA characterized so far are related
to the ability of this molecule to inuence cellular proliferation
and differentiation in several tissues and systems. In this
regard, LPA performs an important role in the vascular system,
where it modulates different effects in vascular smooth muscle
cells (VSMCs) and vascular endothelial cells (VECs), which are
involved in processes like angiogenesis (the formation of new
capillary networks from pre-existing vasculature by sprouting
and/or splitting of capillaries) or vascular maturation. Angio-
genesis involves coordinated proliferation, migration, adhe-
sion, differentiation, and assembly of both VECs and their
surrounding VSMCs, and its dysregulation can lead to diverse
pathological conditions, such as atherosclerosis,55 cardiovas-
cular disease, or development of tumours.
Similarly, and related to the ability of LPA to promote cell
proliferation, the LPA1 receptor is gaining attention as a drug-
gable target for brosis.56,57 This disease involves the formation
of excessive connective tissue, and it has been found to be
strongly inuenced by receptor-mediated LPA signalling in
lung, kidney and skin. Hence, increased epithelial cell
apoptosis, migration and proliferation of lung broblasts,
together with enhanced broblast resistance to apoptosis are
LPA1-mediated processes directly linked to the development ofThis journal is © The Royal Society of Chemistry 2014pulmonary, dermal and kidney brosis. In addition, the results
obtained with a dual LPA1/LPA3 antagonist suggest a possible
implication of the LPA3 receptor. Supporting these data, one
LPA1 antagonist has entered phase II clinical trials for idio-
pathic pulmonary brosis (IPF)58 and another one is in
preclinical stages, indicated for the treatment of liver, lung and
kidney brosis.59
Recent research has also associated the LPA1 receptor with
the initiation and development of rheumatoid arthritis (RA). It
is known that synovial broblasts (SFs), implicated in the
beginning and perpetuation of RA, express all LPA receptors
and that LPA stimulates proliferation, adhesion and migration
of SFs. Accordingly, the LPA1 receptor has been suggested as a
possible therapeutic target in the treatment of this disease.60,61
LPA1 is also the most widely expressed lysophospholipid
receptor in adipose tissue, a fact that makes it an interesting
pharmacological target for the treatment of obesity-associated
metabolic diseases. Obesity, one of the key factors leading to
type II diabetes, is accompanied by an increased ATX-mediated
synthesis of LPA by adipocytes, where LPA exerts different bio-
logical actions through the activation of the LPA1 receptor.62
Finally, it is well known that LPA signalling inuences
cancer-related processes,63 especially via LPA2. Nevertheless,
there is also evidence of LPA1 implication in cancer progression,
specically in ovarian, breast and gastrointestinal ones.LPA1 receptor ligands
Given the importance of the LPA1 receptor in a variety of
pathologies, the need for potent and selective ligands is crucial
to unravel its potential as a therapeutic target, but up to this
moment there are no drugs in the market targeting any of the
LPA receptors.
Although much research is ongoing in this eld,64 the lack of
potent and selective ligands is still an issue. Lipid-resembling
molecules encounter solubility problems and show very high
protein binding with only a small percentage within plasma
available to interact with receptors. Moreover, the abundant cell
surface lipid phosphate phosphohydrolases may rapidly
degrade them. Regarding non-lipid structures, some advances
have been done in the eld of antagonists, as two of them have
currently reached clinical trials.58,65,66 Still, small-molecule
agonists structurally different from LPA have not been
described yet.Agonists of the LPA1 receptor
Detailed studies have been carried out on the search for the
essential patterns required to obtain selective agonism at the
LPA1 receptor.40 The information available so far comes from
LPA analogues, as no structurally different synthetic agonists
have been described yet (Fig. 4).
The rst LPA-based agonist was N-acyl ethanolamide phos-
phoric acid (2-[(9Z)-octadec-9-enoylamino]ethyl dihydrogen
phosphate or NAEPA, 1) described by Sugiura in 1994 (ref. 67) as
an LPA mimetic and later conrmed as a dual LPA1/LPA2
agonist.68 Several changes in its structure have led to ligandsMed. Chem. Commun., 2014, xx, 1–11 | 5
Fig. 4 LPA degradation pathways.
Fig. 6 Structure of OMPT and derivatives.
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40with improved activity and, in some cases, selectivity over the
LPA1 receptor. Initial modications included the introduction
of different substituents in the b-carbon atom (Fig. 5, le panel)
and revealed a strong enantiomer preference, as well as a
decrease in agonist potency when bulky substituents were
introduced. Among all the synthesized compounds, 2–4 stand
out as potent dual LPA1/LPA3 agonists, with a stronger prefer-
ence for LPA1 and activity values similar to LPA [EC50 (LPA1)¼ 7.9,
4.9 and 3.4 nM; EC50 (LPA3) ¼ 321.8, 683.7 and 112.6 nM,
respectively].69
Further replacements of the phosphate group by its
mimetics thiophosphate (Y ¼ S, Z ¼ O, Fig. 5), and the meta-
bolically stabilized phosphorothioate (Y ¼ O, Z ¼ S, Fig. 5) and
phosphonate groups (Y ¼ C, Z ¼ O, Fig. 5) were carried out.
These groups, especially phosphonates, had higher pKa values
than LPA, so a-substituted phosphonates with electronegative
groups at the a-carbon were also prepared in order to maintain
acidity (Fig. 5, right panel). Among them, selective compounds 6
[EC50 (LPA1) ¼ 318 nM] and 7 [EC50 (LPA1) ¼ 221 nM] exhibit an
activity similar to NAEPA at the LPA1 receptor (EC50 ¼ 197 nM),
and compound 5 [EC50 (LPA1) ¼ 40 nM; EC50 (LPA2) ¼ 108 nM]
improved it. It must be noted that analogue 8, bearing an
a-uorophosphonate moiety, more acid than compound 5, was
inactive at the LPA1 receptor, indicating that acidity is not the
only requirement for receptor activation when modifying the
phosphate moiety.70 In fact, other LPA-derived phosphonatesFig. 5 Structure of NAEPA and derivatives.
6 | Med. Chem. Commun., 2014, xx, 1–11
45
50and analogues bearing uoro or diuoro moieties in the a-
carbon act as good LPA2 or LPA3 agonists, but are inactive at
LPA1.71
The LPA analogue (2S)-2-methoxy-3-(thiophosphonooxy)
propyl (9Z)-octadec-9-enoate or OMPT (9) was one of the rst
selective LPA3 agonists, with an EC50 value of 276 nM.72 Its
modication led to diverse structures, such as the enantiomers
10 [EC50 (LPA1) ¼ 790 nM; EC50 (LPA3) ¼ 62 nM] and 11 [EC50
(LPA1) ¼ 571 nM; EC50 (LPA3) ¼ 80 nM], which turned out to be
good LPA3 agonists but also present modest activity at LPA1
(Fig. 6).73 In order to prevent acyl chain migration, other
metabolically stabilizing modications were carried out,
leading to phosphorothioate analogues of sn-2-acyl LPA
(compounds 12–14, Fig. 6). These three compounds displayed
weak LPA1 agonism, but they stand out as potent LPA3, LPA5
and LPA6 agonists.74
The inuence of the position of the acyl chain has also been
studied. For example, sn-2 LPA derivatives resistant to acyl
migration such as 1,1-diuorinated phosphates,75 diuor-
omethyl phosphates76 or a-uorinated phosphonates77 were
synthesized. Unfortunately, none of these compounds was
active at the LPA1 receptor,71 though LPA1 and LPA2 receptors
were reported to show no regioisomeric preference between sn-1
and sn-2 positions.
Cyclic phosphate analogues have also been described as
LPA1 agonists (Fig. 7). The cyclic diuorophosphate 15 was
reported as a weak LPA1–3 agonist [EC50 (LPA1) > 1940 nM; EC50
(LPA2) > 9460 nM; EC50 (LPA3) > 7030 nM].78 In addition, some
acetal phosphatidates, also known as Darmstoff analogues,
have been reported as LPA mimetics. Some of these compounds
are LPA pan-agonists (16–19), though with activity in the low
micromolar range at the LPA1 receptor.79 Again, small structural
modications turn the compounds into antagonists.
In summary, around 20 years aer the discovery of the rst
LPA1 ligands, there is still a lack of potent and selectiveFig. 7 Structure of cyclic phosphate agonists.
This journal is © The Royal Society of Chemistry 2014
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1agonists. Nowadays, the knowledge about the features needed
for the activity has been somehow disclosed, but despite that,
the complete puzzle of the structural requirements for acti-
vating this receptor is not yet fully understood.Fig. 9 Structure of the pan-antagonist bromophosphonate BrP-LPA
(24).
Fig. 10 Structure of cyclic phosphate antagonists.
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The LPA1 antagonist eld is a current focus of pharmaceutical
companies. Structurally, LPA1 antagonists can be classied into
two broad classes: a family closely related to LPA and a second
group formed by compounds whose structures widely differ
from LPA.
Starting with LPA analogues, modication of the agonist
NAEPA (1, Fig. 5) with a bulky substituent in the b-carbon atom
led to compound 20, which turned out to be a dual LPA1/3
antagonist [IC50 (LPA1) ¼ 5210 nM; IC50 (LPA3) ¼ 6450 nM],69
which has been used in vivo in a model of lung brosis.80 An
exhaustive SAR of this structure yielded compounds 21, a
selective LPA1 ligand with moderate activity [IC50 (LPA1) ¼
2490 nM], and 22, which showed increased potency [IC50
(LPA1) ¼ 109 nM; IC50 (LPA3) ¼ 175 nM] and which is ve times
more active than its (S)-enantiomer.81 Further optimizations led
to 23, a dual LPA1/3 antagonist with nanomolar potency [IC50
(LPA1) ¼ 84 nM; IC50 (LPA3) ¼ 48 nM] (Fig. 8).82
Another important LPA analogue is bromophosphonate 24
(Fig. 9), also known as BrP-LPA, an LPA pan-antagonist [IC50
(LPA1) ¼ 1500 nM; IC50 (LPA2) ¼ 1420 nM; IC50 (LPA3) ¼ 1160
nM; IC50 (LPA4) ¼ 266 nM] and ATX inhibitor with in vivo
activity.83 This molecule has contributed to elucidate the
involvement of LPA receptors in the inhibition of tumour
growth84 and in the attenuation of arthritis in animal models.85
Cyclic LPA derivatives have also been described as LPA1
antagonists (Fig. 10). Compound 25 and cyclic phosphor-
othioates 26 and 27 show activity as partial LPA1/LPA3 antago-
nists with moderate potencies [IC50 (LPA1) ¼ 106–941 nM; IC50
(LPA3) ¼ 1270–7720 nM].78
Overall, these series of compounds show the difficulty of
discovering the requirements needed to regulate the pharma-
cology of LPA-derived ligands, as subtle changes in their
structures convert agonists into antagonists and cause drastic
changes in activity. In addition, the coexistence of a polar head
and a long hydrophobic tail becomes a problem in order toFig. 8 Structure of NAEPA-derived antagonists.
This journal is © The Royal Society of Chemistry 2014
45obtain orally active compounds. Thus, high-throughput
screening was used to discover novel hits, structurally different
from LPA, followed by hit to lead processes to improve their
pharmacology.
The rst reported non-lipid dual LPA1/3 antagonist was
compound 28 (Ki16425, Fig. 11)86 [IC50 (LPA1) ¼ 130 nM; IC50
(LPA3) ¼ 2300 nM] which has been widely used as a tool
compound, as it displays in vivo activity.50,61 Several modica-
tions of its structure by different academic groups and phar-
maceutical companies have led to more potent and selective
compounds, some of them even achieving clinical trials.
Based on this scaffold, Amira Pharmaceuticals (currently
Bristol-Myers Squibb) developed a series of isoxazole deriva-
tives. Among them, compounds 29 (AM966),87 [IC50 (LPA1) ¼ 17
nM; IC50 (LPA2) ¼ 1700 nM; IC50 (LPA3) ¼ 1600 nM] and 30
(AM095)88,89 [IC50 (LPA1) ¼ 25 nM; IC50 (LPA2–5) > 8000 nM]
(Fig. 12) stand out as potent LPA1 antagonists with good oral
bioavailability and antibrotic in vivo activity. Moreover, a
compound coming from this series, BMS-986020, whose struc-
ture has not been disclosed yet, is currently facing phase II trials
for the treatment of IPF.58
Hoffman-La Roche's modications of Ki16425 involved
changes in the carboxylic acid and the heterocyclic core,
replacing the isoxazole moiety with pyrazole and triazole rings.
The best compounds were 31, with low nanomolar activity and
good selectivity values [IC50 (LPA1)¼ 25 nM; IC50 (LPA3) > 30 000
nM], and 32, a dual LPA1/LPA3 antagonist [IC50 (LPA1) ¼ 24 nM;
IC50 (LPA3) ¼ 65 nM] (Fig. 13).90
Further exploration of the central heterocycle ring by other
pharmaceutical companies has led to potent antagonists of theFig. 11 Structure of the dual LPA1/3 antagonist Ki16425 (28).
Med. Chem. Commun., 2014, xx, 1–11 | 7
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Fig. 14 Thiazole LPA1 receptor antagonists.
Fig. 12 Isoxazole LPA1 receptor antagonists developed by Amira
Pharmaceuticals.
Fig. 13 Triazole LPA1 receptor antagonists developed by Hoffman-La
Roche.
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such as compound 33, which is a selective LPA1 receptor
antagonist [IC50 (LPA1) < 50 nM; IC50 (LPA3) > 500 nM].91
Introduction of different sulfonamide groups led to LPA1
antagonists with activities in the low nanomolar scale.92,93 For
example, compound 34 (Fig. 14) is an LPA1 antagonist with an
IC50 value of 6.6 nM.
Initially inspired by Ki16425, Sano-Aventis synthesized a
series of non-natural amino acids, such as compound 35
(Fig. 15), with IC50 values lower than 100 nM. It must beFig. 15 Sanofi-Aventis antagonist.
8 | Med. Chem. Commun., 2014, xx, 1–11highlighted that SAR100842 (structure not yet disclosed) is an
LPA1/LPA3 antagonist from this set of compounds, which has
completed phase II clinical trials for systemic sclerosis.66
In conclusion, it is clear that the LPA1 receptor has an
outstanding but yet intriguing role under physiological and
pathological conditions. Thus, the discovery of potent and
selective agonists and antagonists is nowadays a crucial need to
achieve the validation of this receptor as a therapeutic target.50
55LPA1 receptor ligands under clinical
development
The implication of LPA in multiple diseases has attracted
research interest from both academia and pharmaceutical
companies in order to validate the LPA pathway as a source of
novel druggable targets. Focusing on the LPA1 receptor,
preclinical results obtained from LPA1 knockout mice and the
use of specic antagonists in animal disease models have
demonstrated the key role of this receptor in mediating the
pro-brotic effects of LPA in broblasts. Therefore, the chal-
lenge remains to prove that LPA1 antagonists could be
developed as effective therapeutics for the treatment of
brotic disorders, such as IPF, hepatic brosis and systemic
sclerosis. To date, two LPA1 antagonists, BMS-986020 and
SAR100842, have advanced into clinical investigation for the
treatment of IPF58 and systemic sclerosis.66 Furthermore, an
orally bioactive small-molecule LPA1 antagonist developed by
Angion is at a preclinical stage for the treatment of liver, lung
and kidney brosis.59
BMS-986020, initially developed by Amira and then by Bris-
tol-Myers Squibb, has recently completed a phase I study to
assess the pharmacokinetics, metabolism and excretion, as well
as safety and tolerability of a single oral dose. Moreover, a single
sequence study has also been conducted to evaluate the effect of
concomitant administration of BMS-986020 on the pharmaco-
kinetics of rosuvastatin. Currently, two new clinical trials are
recruiting participants: a phase I study to evaluate the rela-
tionship between plasma drug levels and receptor binding in
the lungs using positron emission tomography (PET); and a
phase II trial to determine if once or twice daily administration
of 600 mg of BMS-986020 will reduce the decline in the forced
vital capacity and will be tolerated well in subjects with IPF.
Additionally, a phase I study to assess the drug–drug interaction
in healthy volunteers is announced to start in September 2014.
This study will determine the effect of BMS-986020 on the
pharmacokinetics of montelukast, urbiprofen, and digoxin.65
Sano-Aventis has conducted a phase II trial with the dual
LPA1/LPA3 antagonist SAR100842 to evaluate its safety and
tolerability in an 8 week study in patients with diffuse, cuta-
neous systemic sclerosis.66 This clinical study was completed in
April 2014 and the results have not been reported yet.
In summary, the progression of LPA1 antagonists into clin-
ical trials will hopefully help to ascertain the therapeutic utility
of the LPA1 receptor as a novel target for the treatment of
disorders with high unmet medical need such as IPF.This journal is © The Royal Society of Chemistry 2014
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Lipid-binding GPCRs are potential drug targets for many
diseases including neuropshychiatric and neurodegenerative
disorders, multiple sclerosis, pain, inammation-related
diseases, and cancer. In particular the LPA1 receptor plays
fundamental roles in both the central and the peripheral
nervous system. However, the paucity of currently available
potent and selective (ant)agonists for the different LPA recep-
tors is hampering the validation of this receptor as a thera-
peutically useful target. In this regard, some advances have
been made in terms of the development of antagonists, some of
which are currently undergoing clinical trials. However, the
eld of agonists is still clearly lagging behind as not really
potent and selective agents structurally different from LPA have
been disclosed. In addition, it is likely that the progress in
structural determination of GPCRs will extend also to LPA
receptors, and structures of these receptors in complex with
different ligands can be elucidated in the upcoming future.
These advances should also consider the importance of biased
and allosteric ligands, since they can help to unravel the biology
behind these receptors and to provide new therapeutic solu-
tions for important diseases that lack adequate clinical treat-
ments today.
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